Projected Healthcare Costs Over the Next Decade for Medicare Recipients Aged 65 and Older Living with HIV
Background
The aging population of people with HIV (PWH) in the U.S. presents significant challenges for Medicare, as this demographic is expected to grow substantially over the next decade. With improved survival rates due to antiretroviral therapy (ART), older PWH face increased medical complexity and rising healthcare costs. Understanding these trends is crucial for planning effective healthcare strategies and resource allocation.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
The number of PWH aged 65 years or older is projected to increase significantly from 2026 to 2035.
Healthcare costs for Medicare beneficiaries with HIV are expected to rise, driven largely by ART expenses.
The CHARMED model was developed to simulate clinical and economic outcomes for older PWH.
Projected ART costs for Medicare are substantial, with bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) costing over $3.1 billion in 2023.
A generic ART regimen is anticipated to become available in 2031, potentially reducing costs.
Clinical Implications
The findings emphasize the need for healthcare systems to prepare for the increasing number of older PWH and the associated rise in healthcare costs. Strategies to manage ART expenses and improve care for this population will be essential as they age.
Conclusion
The projected increase in the aging HIV population and associated healthcare costs underscores the importance of effective planning and resource allocation within Medicare. Continued monitoring and adaptation of care strategies will be necessary to meet the needs of this growing demographic.
by Emily P. Hyle, Luke Ang, Grace Luu, Parastu Kasaie, Dannie Dai, Florence Ebem, Jessica Phelan, Satoshi Koiso, Ciara Duggan, Elizabeth Humes, Dori Molozanov, Paul E. Sax, Lucas Gerace, John Giardina, E. John Orav, Tim Horn, Anne M. Neilan, Ankur Pandya, Jose F. Figueroa, Keri N. Althoff, Kenneth A. Freedberg
